{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:11:06Z","timestamp":1794305466329,"version":"4.9.0"},"reference-count":52,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/btyn8678","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:26:33Z","timestamp":1740536793000},"page":"1076-1086","source":"Crossref","is-referenced-by-count":4,"title":["CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization"],"prefix":"10.62347","volume":"17","author":[{"given":"Jie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, Jones DEJ, Lohse AW and Hudson M. Primary sclerosing cholangitis. Lancet 2018; 391: 2547-2559.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U and Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-1188.","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","article-title":"Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan","volume":"21","author":"Tanaka","year":"2014","unstructured":"Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K and Takikawa H. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 2014; 21: 43-50.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U and Ponsioen CY; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055.","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Trivedi PJ, Bowlus CL, Yimam KK, Razavi H and Estes C. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies. Clin Gastroenterol Hepatol 2022; 20: 1687-1700, e1684.","DOI":"10.1016\/j.cgh.2021.08.039"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"JJ","year":"2007","unstructured":"Tischendorf JJ, Hecker H, Krüger M, Manns MP and Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102: 107-114.","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/ecco-jcc\/jjz094","article-title":"Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study","volume":"13","author":"Guerra","year":"2019","unstructured":"Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E and Gisbert JP; Spanish GETECCU group (ENEIDA Project). Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study. J Crohns Colitis 2019; 13: 1492-1500.","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cgh.2018.04.047","article-title":"Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry","volume":"17","author":"Kuo","year":"2019","unstructured":"Kuo A, Gomel R, Safer R, Lindor KD, Everson GT and Bowlus CL. Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry. Clin Gastroenterol Hepatol 2019; 17: 1372-1378.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Luo X and Lu LG. Progress in the management of patients with cholestatic liver disease: where are we and where are we going? J Clin Transl Hepatol 2024; 12: 581-588.","DOI":"10.14218\/JCTH.2023.00519"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Trauner M, Halilbasic E, Tatscher E and Fickert P. Primary sclerosing cholangitis-Diagnosis and treatment 2024. Inn Med (Heidelb) 2024; 65: 347-356.","DOI":"10.1007\/s00108-024-01697-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lindor KD, Kowdley KV and Harrison ME; American College of Gastroenterology. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015; 110: 646-659; quiz 660.","DOI":"10.1038\/ajg.2015.112"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2008.02.002","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"48","author":"Silveira","year":"2008","unstructured":"Silveira MG and Lindor KD. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 2008; 48: 692-694.","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis","volume":"58","author":"Hansen","year":"2013","unstructured":"Hansen JD, Kumar S, Lo WK, Poulsen DM, Halai UA and Tater KC. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2013; 58: 3079-3087.","journal-title":"Dig Dis Sci"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Davey Smith G and Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23: R89-98.","DOI":"10.1093\/hmg\/ddu328"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"CA","year":"2017","unstructured":"Emdin CA, Khera AV and Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-1926.","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-024-02848-5","article-title":"Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes","volume":"25","author":"Liu","year":"2024","unstructured":"Liu Z, Peng Z, Lin H, Zhou K, Liang L, Cao J, Huang Z and Mei J. Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes. Respir Res 2024; 25: 217.","journal-title":"Respir Res"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R, Overington JP, Hingorani AD and Casas JP. The druggable genome and support for target identification and validation in drug development. Sci Transl Med 2017; 9: eaag1166.","DOI":"10.1126\/scitranslmed.aag1166"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10654-018-0424-6","article-title":"Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates","volume":"33","author":"Burgess","year":"2018","unstructured":"Burgess S and Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. Eur J Epidemiol 2018; 33: 947-952.","journal-title":"Eur J Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","unstructured":"Burgess S and Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011; 40: 755-764.","journal-title":"Int J Epidemiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/ije\/dyw220","article-title":"Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic","volume":"45","author":"Bowden","year":"2016","unstructured":"Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA and Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 2016; 45: 1961-1974.","journal-title":"Int J Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","unstructured":"Burgess S, Butterworth A and Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-665.","journal-title":"Genet Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/bioinformatics\/btz749","article-title":"Bayesian weighted Mendelian randomization for causal inference based on summary statistics","volume":"36","author":"Zhao","year":"2020","unstructured":"Zhao J, Ming J, Hu X, Chen G, Liu J and Yang C. Bayesian weighted Mendelian randomization for causal inference based on summary statistics. Bioinformatics 2020; 36: 1501-1508.","journal-title":"Bioinformatics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method","volume":"32","author":"Burgess","year":"2017","unstructured":"Burgess S and Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-389.","journal-title":"Eur J Epidemiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC and Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-314.","journal-title":"Genet Epidemiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"FP","year":"2017","unstructured":"Hartwig FP, Davey Smith G and Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017; 46: 1985-1998.","journal-title":"Int J Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Bowden J, Hemani G and Davey Smith G. Invited commentary: detecting individual and global horizontal pleiotropy in Mendelian randomization-a job for the humble heterogeneity statistic? Am J Epidemiol 2018; 187: 2681-2685.","DOI":"10.1093\/aje\/kwy185"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ije\/dyx002","article-title":"Pleiotropy-robust Mendelian randomization","volume":"47","author":"van Kippersluis","year":"2018","unstructured":"van Kippersluis H and Rietveld CA. Pleiotropy-robust Mendelian randomization. Int J Epidemiol 2018; 47: 1279-1288.","journal-title":"Int J Epidemiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/hep.32183","article-title":"Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study","volume":"75","author":"Chen","year":"2022","unstructured":"Chen L, Yang H, Li H, He C, Yang L and Lv G. Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study. Hepatology 2022; 75: 785-796.","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"707617","DOI":"10.3389\/fimmu.2021.707617","article-title":"Genetic associations between IL-6 and the development of autoimmune arthritis are gender-specific","volume":"12","author":"Hong","year":"2021","unstructured":"Hong J, Qu Z, Ji X, Li C, Zhang G, Jin C, Wang J, Zhang Y, Shen Y, Meng J, Zhou C, Fang C, Wang W and Yan S. Genetic associations between IL-6 and the development of autoimmune arthritis are gender-specific. Front Immunol 2021; 12: 707617.","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ije\/dyu005","article-title":"Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome","volume":"43","author":"Burgess","year":"2014","unstructured":"Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 2014; 43: 922-929.","journal-title":"Int J Epidemiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41467-018-03371-0","article-title":"Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits","volume":"9","author":"Wu","year":"2018","unstructured":"Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, Lloyd-Jones LR, Marioni RE, Martin NG, Montgomery GW, Deary IJ, Wray NR, Visscher PM, McRae AF and Yang J. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun 2018; 9: 918.","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.12688\/wellcomeopenres.16374.2","article-title":"0: updates to an R package for performing Mendelian randomization analyses using summarized data","volume":"5","author":"Broadbent","year":"2020","unstructured":"Broadbent JR, Foley CN, Grant AJ, Mason AM, Staley JR and Burgess S. MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome Open Res 2020; 5: 252.","journal-title":"Wellcome Open Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","unstructured":"Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD and van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164.","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.v18.i1.1","article-title":"Recurrence and rejection in liver transplantation for primary sclerosing cholangitis","volume":"18","author":"Fosby","year":"2012","unstructured":"Fosby B, Karlsen TH and Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15.","journal-title":"World J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jcmgh.2024.01.023","article-title":"Myeloid deletion of Cdc42 protects liver from hepatic ischemia-reperfusion injury via inhibiting macrophage-mediated inflammation in mice","volume":"17","author":"He","year":"2024","unstructured":"He J, Tang MY, Liu LX, Kong CX, Chen W, Wang L, Zhi SB, Sun HW, Huang YC, Chen GY, Xin HB and Deng KY. Myeloid deletion of Cdc42 protects liver from hepatic ischemia-reperfusion injury via inhibiting macrophage-mediated inflammation in mice. Cell Mol Gastroenterol Hepatol 2024; 17: 965-981.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cell.2007.01.010","article-title":"Phosphoinositides specify polarity during epithelial organ development","volume":"128","author":"Comer","year":"2007","unstructured":"Comer FI and Parent CA. Phosphoinositides specify polarity during epithelial organ development. Cell 2007; 128: 239-240.","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST0330891","article-title":"Rho GTPases and the control of cell behaviour","volume":"33","author":"Hall","year":"2005","unstructured":"Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005; 33: 891-895.","journal-title":"Biochem Soc Trans"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.1216380","article-title":"Cell polarity: quantitative modeling as a tool in cell biology","volume":"336","author":"Mogilner","year":"2012","unstructured":"Mogilner A, Allard J and Wollman R. Cell polarity: quantitative modeling as a tool in cell biology. Science 2012; 336: 175-179.","journal-title":"Science"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1042\/BST20200468","article-title":"Activation of STAT transcription factors by the Rho-family GTPases","volume":"48","author":"Corry","year":"2020","unstructured":"Corry J, Mott HR and Owen D. Activation of STAT transcription factors by the Rho-family GTPases. Biochem Soc Trans 2020; 48: 2213-2227.","journal-title":"Biochem Soc Trans"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3389\/fonc.2019.00958","article-title":"Rational targeting of Cdc42 overcomes drug resistance of multiple myeloma","volume":"9","author":"Nguyen","year":"2019","unstructured":"Nguyen P, Chakrabarti J, Li Y, Kalim KW, Zhang M, Zhang L, Zheng Y and Guo F. Rational targeting of Cdc42 overcomes drug resistance of multiple myeloma. Front Oncol 2019; 9: 958.","journal-title":"Front Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/bjc.2017.335","article-title":"Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis","volume":"117","author":"Nandy","year":"2017","unstructured":"Nandy SB, Orozco A, Lopez-Valdez R, Roberts R, Subramani R, Arumugam A, Dwivedi AK, Stewart V, Prabhakar G, Jones S and Lakshmanaswamy R. Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis. Br J Cancer 2017; 117: 1665-1675.","journal-title":"Br J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","article-title":"Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets","volume":"24","author":"JH","year":"2023","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman ÅK, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J, Folkersen L, Herder C, Jonsson L, Bergen SE, Gieger C, Needham EJ, Surendran P; Estonian Biobank Research Team, Paul DS, Polasek O, Thorand B, Grallert H, Roden M, Võsa U, Esko T, Hayward C, Johansson Å, Gyllensten U, Powell N, Hansson O, Mattsson-Carlgren N, Joshi PK, Danesh J, Padyukov L, Klareskog L, Landén M, Wilson JF, Siegbahn A, Wallentin L, Mälarstig A, Butterworth AS and Peters JE. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 2023; 24: 1540-1551.","journal-title":"Nat Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/hep.31140","article-title":"Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC)","volume":"72","author":"LK","year":"2020","unstructured":"Kunzmann LK, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, Böttcher M, Petersen BS, Weiler-Normann C, Hess LU, Ahrenstorf AE, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse AW, Franke A, Herkel J, Schramm C and Schwinge D. Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC). Hepatology 2020; 72: 1310-1326.","journal-title":"Hepatology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/j.1478-3231.2011.02635.x","article-title":"Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis","volume":"31","author":"Mueller","year":"2011","unstructured":"Mueller T, Beutler C, Picó AH, Shibolet O, Pratt DS, Pascher A, Neuhaus P, Wiedenmann B, Berg T and Podolsky DK. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int 2011; 31: 1574-1588.","journal-title":"Liver Int"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2018.05.018","article-title":"Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice","volume":"69","author":"ME","year":"2018","unstructured":"Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O’Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF and Gores GJ. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 2018; 69: 676-686.","journal-title":"J Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"4807145","DOI":"10.1155\/2018\/4807145","article-title":"M1-polarized macrophages promote self-renewing phenotype of hepatic progenitor cells with Jagged1-Notch signalling involved: relevance in primary sclerosing cholangitis","volume":"2018","author":"Li","year":"2018","unstructured":"Li H, Sun S, Lei Q, Lei P, Cai X, Wan C and Shen G. M1-polarized macrophages promote self-renewing phenotype of hepatic progenitor cells with Jagged1-Notch signalling involved: relevance in primary sclerosing cholangitis. J Immunol Res 2018; 2018: 4807145.","journal-title":"J Immunol Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41419-021-03623-w","article-title":"CREG ameliorates the phenotypic switching of cardiac fibroblasts after myocardial infarction via modulation of CDC42","volume":"12","author":"Liu","year":"2021","unstructured":"Liu D, Tian X, Liu Y, Song H, Cheng X, Zhang X, Yan C and Han Y. CREG ameliorates the phenotypic switching of cardiac fibroblasts after myocardial infarction via modulation of CDC42. Cell Death Dis 2021; 12: 355.","journal-title":"Cell Death Dis"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Hu X, Gan L, Tang Z, Lin R, Liang Z, Li F, Zhu C, Han X, Zheng R, Shen J, Yu J, Luo N, Peng W, Tan J, Li X, Fan J, Wen Q, Wang X, Li J, Zheng X, Liu Q, Guo J, Shi GP, Mao H, Chen W, Yin S and Zhou Y. A natural small molecule mitigates kidney fibrosis by targeting Cdc42-mediated GSK-3β\/β-catenin signaling. Adv Sci (Weinh) 2024; 11: e2307850.","DOI":"10.1002\/advs.202307850"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1449423","DOI":"10.3389\/fcimb.2024.1449423","article-title":"Cdc42 improve SARS-CoV-2 spike protein-induced cellular senescence through activating of Wnt\/β-Catenin signaling pathway","volume":"14","author":"Nong","year":"2024","unstructured":"Nong C, Wu Z, Yang C, Xu W, Luo L, Zhou J, Shen L, Chen Y, Yuan Y and Hu G. Cdc42 improve SARS-CoV-2 spike protein-induced cellular senescence through activating of Wnt\/β-Catenin signaling pathway. Front Cell Infect Microbiol 2024; 14: 1449423.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/pharmaceutics16101301","article-title":"PLGA-PEG nanoparticles loaded with Cdc42 inhibitor for colorectal cancer targeted therapy","volume":"16","author":"Kadyr","year":"2024","unstructured":"Kadyr S, Zhuraliyeva A, Yermekova A, Makhambetova A, Kaldybekov DB, Mun EA, Bulanin D, Askarova SN and Umbayev BA. PLGA-PEG nanoparticles loaded with Cdc42 inhibitor for colorectal cancer targeted therapy. Pharmaceutics 2024; 16: 1301.","journal-title":"Pharmaceutics"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"117329","DOI":"10.1016\/j.biopha.2024.117329","article-title":"Pharmacokinetic profiling of ZCL-278, a cdc42 inhibitor, and its effectiveness against chronic kidney disease","volume":"179","author":"Zhang","year":"2024","unstructured":"Zhang Q, Qin Z, Wang Q, Lu L, Wang J, Lu M, Wang P, Liu D, Zhou C and Liu Z. Pharmacokinetic profiling of ZCL-278, a cdc42 inhibitor, and its effectiveness against chronic kidney disease. Biomed Pharmacother 2024; 179: 117329.","journal-title":"Biomed Pharmacother"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0160798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:47Z","timestamp":1766023127000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0160798.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/btyn8678","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}